Perspective: lessons learned from molecular genetic studies of thyroid cancer--insights into pathogenesis and tumor-specific therapeutic targets.
Fagin
James A
JA
Division of Endocrinology and Metabolism, University of Cincinnati College of Medicine, Cincinnati, Ohio 45267-0547, USA. James.Fagin@uc.edu
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use; D002291:Carcinoma, Papillary / Q000188:drug therapy / Q000235:genetics; D018265:Carcinoma, Papillary, Follicular / Q000188:drug therapy / Q000235:genetics; D029721:Drosophila Proteins; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D006801:Humans; D008967:Molecular Biology / Q000639:trends*; D009381:Neoplasms, Radiation-Induced / Q000188:drug therapy / Q000235:genetics; D011518:Proto-Oncogene Proteins / Q000037:antagonists & inhibitors / Q000235:genetics*; D051096:Proto-Oncogene Proteins c-ret; D020794:Receptor Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors / Q000235:genetics*; D013964:Thyroid Neoplasms / Q000188:drug therapy / Q000235:genetics* / Q000473:pathology
D000970:Antineoplastic Agents; D029721:Drosophila Proteins; D004791:Enzyme Inhibitors; D011518:Proto-Oncogene Proteins; D051096:Proto-Oncogene Proteins c-ret; D020794:Receptor Protein-Tyrosine Kinases; C416649:Ret protein, Drosophila